Teja Bedi, MD
Medical Oncology · San Mateo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · County of San Mateo · Permanente Medical Group Inc
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · San Mateo Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bedi’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A94053 · Current
Licensed to practise in California · since 2006 · expires 2027-09-30 · University of Mumbai, Lokmanya Tilak Municipal Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- San Mateo Medical CenterSan Mateo, CAAcute Care Hospital · Government - Local · Has an emergency departmentPart of San Mateo County HealthPatients rate it 3 of 5 · 68% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for San Mateo Medical Center
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 3 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.34 (0.25 to 2.43) · 45 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.48 to 1.47) | No different | Jul 2022 – Jun 2024 |
| Death rate for pneumonia patientsComplications and deaths | 13.9 · 25 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 258 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 379 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 381 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.44 (0.82 to 6.05) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.64 (0.92 to 4.37) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.53 (0 to 1.76) · 296 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.661 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 47 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -2.3 · 25 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.4 to 18.9) · 167 cases | No different | Jan 2022 – Dec 2024 |
What patients said (208 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$4,271
Medicare paid this office $4,271 for 27 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 11 | $1,294 | $108 |
Who their Medicare patients are
27 Original Medicare patients in 2024. Average age 76 · Women 48% · Also on Medicaid 48% · Health risk score 1.82. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 70%.
The office billed $11,712, Medicare allowed $5,359 and paid $4,271; for 36 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 27 | 36 | 76 | 1.82 | $11,712 | $4,271 |
| 2021 | 11 | 26 | 66 | 1.20 | $5,978 | $2,305 |
| 2020 | 31 | 55 | 72 | 1.99 | $9,953 | $3,909 |
| 2019 | 12 | 25 | 71 | 2.86 | $6,856 | $1,897 |
| 2018 | 55 | 108 | 69 | 1.82 | $29,571 | $7,288 |
| 2017 | 85 | 217 | 70 | 1.66 | $57,568 | $12,957 |
| 2016 | 84 | 300 | 68 | 1.51 | $72,043 | $16,970 |
| 2015 | 76 | 205 | 68 | 1.32 | $51,063 | $12,950 |
| 2014 | 72 | 206 | 67 | 1.38 | $51,049 | $13,092 |
| 2013 | 79 | 230 | 68 | 1.35 | $55,416 | $14,925 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2020: 1 service
| Telephone medical discussion with physician, 11-20 minutes | 19 | $882 | $42 |
2018: 1 service
| Return visit (30+ min) | 42 | $4,932 | $62 |
2017: 2 services
| Return visit (30+ min) | 74 | $10,233 | $57 |
| New patient visit (45+ min) | 14 | $1,354 | $97 |
2016: 3 services
| Return visit (30+ min) | 72 | $12,853 | $58 |
| New patient visit (45+ min) | 17 | $1,739 | $102 |
| Short return visit | 11 | $777 | $21 |
2015: 3 services
| Return visit (30+ min) | 57 | $10,010 | $63 |
| New patient visit (45+ min) | 19 | $1,987 | $105 |
| Short return visit (20+ min) | 18 | $695 | $35 |
2014: 2 services
| Return visit (30+ min) | 61 | $9,782 | $62 |
| New patient visit (45+ min) | 16 | $1,744 | $109 |
2013: 3 services
| Return visit (30+ min) | 61 | $10,508 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,705 | $90 |
| New patient visit (45+ min) | 11 | $1,236 | $112 |
Medicaid work
$102,448 in 2024
Medicaid paid $102,448 for 827 billed services this clinician did in 2024, up to 60 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 475 | $51,575 |
| Long return visit (40+ min) | 327 | $50,873 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 25 | $0 |
| 2024 | 827 | 3 | 60 | $102,448 |
| 2023 | 1,184 | 5 | 83 | $68,884 |
| 2022 | 1,187 | 2 | 87 | $68,954 |
| 2021 | 798 | 5 | 78 | $48,244 |
| 2020 | 742 | 2 | 65 | $44,852 |
| 2019 | 879 | 1 | 79 | $49,255 |
| 2018 | 809 | 1 | 70 | $45,750 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 818 | $48,431 |
| Long return visit (40+ min) | 147 | $13,348 |
| Short return visit (20+ min) | 167 | $6,092 |
| Sign language or oral interpretive services, per 15 minutes | 28 | $723 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 24 | $291 |
2022
| Return visit (30+ min) | 1,030 | $62,928 |
| Short return visit (20+ min) | 157 | $6,025 |
2021
| Return visit (30+ min) | 684 | $41,967 |
| Long return visit (40+ min) | 33 | $2,535 |
| Short return visit (20+ min) | 52 | $2,015 |
| New patient visit (45+ min) | 15 | $1,328 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 14 | $398 |
2020
| Return visit (30+ min) | 730 | $44,362 |
| Short return visit (20+ min) | 12 | $490 |
2019
| Return visit (30+ min) | 879 | $49,255 |
2018
| Return visit (30+ min) | 809 | $45,750 |
Drugs they prescribed that Part D paid
$3,013,600
Pharmacies billed $3,013,600 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
342 generic and fewer than 11 brand-name prescriptions · $3,013,600 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Bosulif | 23 | $450,843 | $19,602 |
| Imbruvica | 27 | $440,913 | $16,330 |
| Sprycel | 18 | $328,700 | $18,261 |
| Xtandi | 19 | $305,099 | $16,058 |
| Piqray | 13 | $293,614 | $22,586 |
See all 21 drugs
| Bosulif | 23 | $450,843 | $19,602 |
| Imbruvica | 27 | $440,913 | $16,330 |
| Sprycel | 18 | $328,700 | $18,261 |
| Xtandi | 19 | $305,099 | $16,058 |
| Piqray | 13 | $293,614 | $22,586 |
| Alecensa | 16 | $273,350 | $17,084 |
| Lorbrena | 12 | $254,774 | $21,231 |
| Gefitinib | 12 | $74,448 | $6,204 |
| Eliquis | 21 | $17,247 | $821 |
| Xarelto | 13 | $7,247 | $557 |
| Anastrozole | 69 | $7,171 | $104 |
| Exemestane | 13 | $4,262 | $328 |
| Imatinib Mesylate | 14 | $1,747 | $125 |
| Dexamethasone | 15 | $474 | $32 |
| Loperamide | 12 | $331 | $28 |
| Famotidine | 18 | $281 | $16 |
| Omeprazole | 25 | $265 | $11 |
| Ondansetron | 17 | $253 | $15 |
| Hydroxyurea | 22 | $242 | $11 |
| Acyclovir | 11 | $177 | $16 |
| Alendronate | 14 | $148 | $11 |
Year by year
| 2024 | 557 | 80 | None | None | $3,013,600 |
| 2023 | 578 | 82 | None | None | $2,456,902 |
| 2022 | 601 | 76 | 4% (24) | 30% | $2,240,295 |
| 2021 | 533 | 79 | 2% (12) | 32% | $2,023,627 |
| 2020 | 570 | 78 | None | 32% | $1,973,814 |
| 2019 | 531 | 76 | 9% (47) | 19% | $1,143,946 |
| 2018 | 612 | 87 | 8% (49) | 21% | $1,270,820 |
| 2017 | 601 | 83 | 10% (62) | 20% | $1,071,024 |
| 2016 | 595 | 74 | 12% (71) | None | $892,542 |
| 2015 | 757 | 95 | 14% (105) | 14% | $661,400 |
| 2014 | 530 | 79 | 12% (65) | 13% | $374,737 |
| 2013 | 586 | 71 | 13% (77) | 15% | $342,948 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Bosulif | 23 | $487,764 | $21,207 |
| Imbruvica | 25 | $397,878 | $15,915 |
| Xtandi | 21 | $301,214 | $14,344 |
| Piqray | 13 | $296,068 | $22,774 |
| Sandostatin Lar Depot | 17 | $79,221 | $4,660 |
| Eliquis | 13 | $12,657 | $974 |
| Xarelto | 12 | $6,369 | $531 |
| Anastrozole | 101 | $3,503 | $35 |
| Imatinib Mesylate | 12 | $1,498 | $125 |
| Prochlorperazine Maleate | 21 | $752 | $36 |
| Ondansetron | 25 | $723 | $29 |
| Dexamethasone | 18 | $551 | $31 |
| Hydroxyurea | 15 | $529 | $35 |
| Letrozole | 11 | $451 | $41 |
| Acyclovir | 13 | $323 | $25 |
| Omeprazole | 18 | $313 | $17 |
| Hydroxyzine | 11 | $123 | $11 |
| Amlodipine Besylate | 11 | $44 | $4 |
| Allopurinol | 12 | $42 | $4 |
2022: 19 drugs
| Bosulif | 23 | $438,462 | $19,064 |
| Imbruvica | 26 | $388,947 | $14,960 |
| Xtandi | 23 | $316,063 | $13,742 |
| Ibrance | 17 | $257,059 | $15,121 |
| Revlimid | 13 | $219,832 | $16,910 |
| Sprycel | 18 | $205,362 | $11,409 |
| Sandostatin Lar Depot | 11 | $50,266 | $4,570 |
| Xarelto | 13 | $6,574 | $506 |
| Imatinib Mesylate | 13 | $2,443 | $188 |
| Anastrozole | 120 | $2,048 | $17 |
| Hydroxyurea | 18 | $860 | $48 |
| Ondansetron | 29 | $818 | $28 |
| Loperamide | 16 | $741 | $46 |
| Omeprazole | 29 | $539 | $19 |
| Tamoxifen Citrate | 13 | $474 | $36 |
| Prochlorperazine Maleate | 11 | $331 | $30 |
| Letrozole | 26 | $262 | $10 |
| Alendronate | 13 | $193 | $15 |
| Allopurinol | 11 | $55 | $5 |
2021: 15 drugs
| Xtandi | 33 | $410,292 | $12,433 |
| Bosulif | 23 | $408,528 | $17,762 |
| Imbruvica | 26 | $366,953 | $14,114 |
| Sprycel | 19 | $220,527 | $11,607 |
| Ibrance | 16 | $214,820 | $13,426 |
| Revlimid | 11 | $204,253 | $18,568 |
| Imatinib Mesylate | 32 | $31,183 | $974 |
| Anastrozole | 81 | $1,718 | $21 |
| Tamoxifen Citrate | 21 | $857 | $41 |
| Hydroxyurea | 22 | $762 | $35 |
| Loperamide | 12 | $295 | $25 |
| Letrozole | 12 | $268 | $22 |
| Omeprazole | 14 | $190 | $14 |
| Tamsulosin | 14 | $176 | $13 |
| Ondansetron | 12 | $122 | $10 |
2020: 17 drugs
| Revlimid | 24 | $397,589 | $16,566 |
| Bosulif | 23 | $383,297 | $16,665 |
| Imbruvica | 26 | $342,562 | $13,175 |
| Xtandi | 24 | $300,945 | $12,539 |
| Pomalyst | 12 | $229,812 | $19,151 |
| Sprycel | 19 | $209,121 | $11,006 |
| Imatinib Mesylate | 41 | $17,973 | $438 |
| Xarelto | 11 | $5,404 | $491 |
| Tamoxifen Citrate | 26 | $954 | $37 |
| Anastrozole | 59 | $943 | $16 |
| Alendronate | 42 | $462 | $11 |
| Hydroxyurea | 17 | $450 | $26 |
| Levothyroxine | 18 | $300 | $17 |
| Tamsulosin | 14 | $191 | $14 |
| Omeprazole | 14 | $172 | $12 |
| Gabapentin | 15 | $119 | $8 |
| Allopurinol | 12 | $71 | $6 |
2019: 17 drugs
| Revlimid | 14 | $217,633 | $15,545 |
| Sprycel | 17 | $216,871 | $12,757 |
| Bosulif | 12 | $184,493 | $15,374 |
| Imatinib Mesylate | 25 | $85,122 | $3,405 |
| Tamoxifen Citrate | 18 | $1,339 | $74 |
| Anastrozole | 60 | $786 | $13 |
| Dexamethasone | 14 | $414 | $30 |
| Hydrocodone-Acetaminophen | 19 | $367 | $19 |
| Ondansetron | 26 | $329 | $13 |
| Morphine Sulfate Er | 18 | $300 | $17 |
| Alendronate | 43 | $209 | $5 |
| Omeprazole | 14 | $168 | $12 |
| Prochlorperazine Maleate | 11 | $145 | $13 |
| Lorazepam | 20 | $126 | $6 |
| Gabapentin | 12 | $86 | $7 |
| Sulfamethoxazole-Trimethoprim | 11 | $73 | $7 |
| Prednisone | 12 | $59 | $5 |
2018: 16 drugs
| Revlimid | 23 | $328,140 | $14,267 |
| Afinitor | 18 | $265,456 | $14,748 |
| Sprycel | 17 | $222,270 | $13,075 |
| Imatinib Mesylate | 32 | $179,201 | $5,600 |
| Exjade | 12 | $118,925 | $9,910 |
| Anastrozole | 66 | $1,985 | $30 |
| Ondansetron | 32 | $1,235 | $39 |
| Tamoxifen Citrate | 12 | $923 | $77 |
| Letrozole | 25 | $880 | $35 |
| Hydrocodone-Acetaminophen | 36 | $464 | $13 |
| Alendronate | 41 | $394 | $10 |
| Dexamethasone | 17 | $390 | $23 |
| Omeprazole | 17 | $191 | $11 |
| Prochlorperazine Maleate | 24 | $153 | $6 |
| Lorazepam | 24 | $85 | $4 |
| Furosemide | 13 | $25 | $2 |
2017: 16 drugs
| Revlimid | 22 | $279,175 | $12,690 |
| Sprycel | 21 | $256,848 | $12,231 |
| Sutent | 11 | $112,080 | $10,189 |
| Anastrozole | 68 | $3,003 | $44 |
| Ondansetron | 28 | $1,260 | $45 |
| Tamoxifen Citrate | 14 | $850 | $61 |
| Dexamethasone | 21 | $388 | $18 |
| Hydrocodone-Acetaminophen | 30 | $309 | $10 |
| Omeprazole | 27 | $255 | $9 |
| Letrozole | 11 | $254 | $23 |
| Alendronate | 16 | $253 | $16 |
| Oxycodone-Acetaminophen | 15 | $244 | $16 |
| Levetiracetam | 18 | $228 | $13 |
| Amlodipine Besylate | 16 | $166 | $10 |
| Prochlorperazine Maleate | 14 | $136 | $10 |
| Lorazepam | 20 | $93 | $5 |
2016: 17 drugs
| Sprycel | 20 | $225,568 | $11,278 |
| Gleevec | 19 | $196,583 | $10,346 |
| Revlimid | 16 | $185,740 | $11,609 |
| Anastrozole | 82 | $1,260 | $15 |
| Morphine Sulfate Er | 22 | $987 | $45 |
| Tamsulosin | 16 | $486 | $30 |
| Hydrocodone-Acetaminophen | 18 | $415 | $23 |
| Omeprazole | 34 | $241 | $7 |
| Alendronate | 26 | $195 | $8 |
| Prochlorperazine Maleate | 21 | $193 | $9 |
| Ondansetron | 12 | $179 | $15 |
| Letrozole | 15 | $165 | $11 |
| Losartan | 12 | $122 | $10 |
| Lorazepam | 25 | $68 | $3 |
| Atenolol | 12 | $56 | $5 |
| Ranitidine | 12 | $45 | $4 |
| Fluoxetine | 11 | $23 | $2 |
2015: 20 drugs
| Gleevec | 18 | $182,293 | $10,127 |
| Revlimid | 13 | $134,734 | $10,364 |
| Sutent | 11 | $97,412 | $8,856 |
| Anastrozole | 166 | $2,275 | $14 |
| Morphine Sulfate Er | 21 | $1,999 | $95 |
| Tamoxifen Citrate | 29 | $919 | $32 |
| Hydrocodone-Acetaminophen | 39 | $889 | $23 |
| Oxycodone | 21 | $546 | $26 |
| Hydroxyurea | 12 | $332 | $28 |
| Omeprazole | 42 | $324 | $8 |
| Oxycodone-Acetaminophen | 14 | $290 | $21 |
| Ondansetron | 16 | $281 | $18 |
| Alendronate | 34 | $263 | $8 |
| Letrozole | 24 | $226 | $9 |
| Ranitidine | 26 | $188 | $7 |
| Dexamethasone | 14 | $163 | $12 |
| Prochlorperazine Maleate | 16 | $141 | $9 |
| Sulfamethoxazole-Trimethoprim | 13 | $95 | $7 |
| Lorazepam | 27 | $90 | $3 |
| Atenolol | 12 | $77 | $6 |
2014: 14 drugs
| Revlimid | 17 | $162,195 | $9,541 |
| Anastrozole | 88 | $4,073 | $46 |
| Tamoxifen Citrate | 36 | $1,109 | $31 |
| Letrozole | 27 | $663 | $25 |
| Hydrocodone-Acetaminophen | 35 | $587 | $17 |
| Ondansetron | 12 | $363 | $30 |
| Hydroxyurea | 14 | $330 | $24 |
| Alendronate | 27 | $297 | $11 |
| Potassium Chloride | 12 | $232 | $19 |
| Omeprazole | 15 | $196 | $13 |
| Zolpidem | 29 | $146 | $5 |
| Ranitidine | 13 | $144 | $11 |
| Amlodipine Besylate | 11 | $94 | $9 |
| Sulfamethoxazole-Trimethoprim | 14 | $84 | $6 |
2013: 14 drugs
| Revlimid | 11 | $99,756 | $9,069 |
| Anastrozole | 97 | $4,842 | $50 |
| Letrozole | 25 | $1,052 | $42 |
| Tamoxifen Citrate | 40 | $777 | $19 |
| Megestrol Acetate | 12 | $479 | $40 |
| Alendronate | 42 | $420 | $10 |
| Hydrocodone-Acetaminophen | 36 | $224 | $6 |
| Ranitidine | 21 | $170 | $8 |
| Oxycodone-Acetaminophen | 13 | $150 | $12 |
| Dexamethasone | 23 | $147 | $6 |
| Amlodipine Besylate | 15 | $144 | $10 |
| Zolpidem | 19 | $103 | $5 |
| Sulfamethoxazole-Trimethoprim | 12 | $73 | $6 |
| Lorazepam | 14 | $63 | $5 |
Money from drug and device companies
$13 in 2022
| 2022 | 1 | 1 | None | $13 |
| 2021 | 1 | 3 | None | $42 |
| 2020 | 1 | 4 | None | $49 |
| 2019 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Opdivo | $13 | 1 payment
|
See the published payment
| E.R. Squibb & Sons L.L.C. | Meals · 2022-12-12 | Opdivo | $13 |
See earlier years (2021, 2020, 2019)
2021: $42
| Pfizer | Inlyta | $42 | 3 payments
|
2020: $49
| Pfizer | Lorbrena | $49 | 4 payments
|
2019: $12
| Pfizer | Ibrance | $12 | 1 payment
|
Professional record
- NPI
- 1871777573
- Licence
- CA A94053California A94053: Current · expires 2027-09-30
- Group
- County of San Mateo · Permanente Medical Group Inc
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X)
- Mailing address
- 2589 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2007-12-18
- NPI last updated
- 2024-11-07
- NPI record certified
- 2024-11-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 222 W 39th Ave, San Mateo, CA, 94403